- Home
- SSKN vs KPRX Comparison
SSKN vs KPRX Comparison
Compare SSKN & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSKN
- KPRX
- Stock Information
- Founded
- SSKN 1989
- KPRX 1998
- Country
- SSKN United States
- KPRX United States
- Employees
- SSKN N/A
- KPRX N/A
- Industry
- SSKN Medical/Dental Instruments
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SSKN Health Care
- KPRX Health Care
- Exchange
- SSKN Nasdaq
- KPRX Nasdaq
- Market Cap
- SSKN 13.5M
- KPRX 11.0M
- IPO Year
- SSKN 2005
- KPRX N/A
- Fundamental
- Price
- SSKN $3.10
- KPRX $3.18
- Analyst Decision
- SSKN
- KPRX Strong Buy
- Analyst Count
- SSKN 0
- KPRX 1
- Target Price
- SSKN N/A
- KPRX $10.00
- AVG Volume (30 Days)
- SSKN 14.5K
- KPRX 45.3K
- Earning Date
- SSKN 11-13-2024
- KPRX 11-19-2024
- Dividend Yield
- SSKN N/A
- KPRX N/A
- EPS Growth
- SSKN N/A
- KPRX N/A
- EPS
- SSKN N/A
- KPRX 1.53
- Revenue
- SSKN $32,729,999.00
- KPRX $16,020,000.00
- Revenue This Year
- SSKN $0.14
- KPRX N/A
- Revenue Next Year
- SSKN $12.67
- KPRX N/A
- P/E Ratio
- SSKN N/A
- KPRX $2.29
- Revenue Growth
- SSKN N/A
- KPRX N/A
- 52 Week Low
- SSKN $2.51
- KPRX $3.00
- 52 Week High
- SSKN $7.00
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- SSKN 51.31
- KPRX 43.73
- Support Level
- SSKN $2.91
- KPRX $3.47
- Resistance Level
- SSKN $3.52
- KPRX $3.75
- Average True Range (ATR)
- SSKN 0.24
- KPRX 0.22
- MACD
- SSKN 0.00
- KPRX -0.03
- Stochastic Oscillator
- SSKN 45.45
- KPRX 0.00
About SSKN Strata Skin Sciences Inc.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.